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Abstract
Background Blood transfusion is often required in total
knee replacement; various methods of blood preservation
have been studied. The best solution is to reduce the loss of
blood during and after surgery.
Materials and methods We designed this study to eval-
uate the hemostatic efficacy and safety of fibrin tissue
adhesive (Quixil) in patients receiving total knee arthro-
plasty [low contact stress (LCS, DePuy, Warsaw, IN, US)
cementless total knee replacement (TKR)] with a pro-
spective, randomized, standard treatment controlled study.
Thirty-five patients were randomized to receive treatment
with fibrin tissue adhesive (treatment group), and 35 were
randomized to be managed with postoperative blood
recovery and reinfusion (control group). Blood loss in
suction drain, decrease in hemoglobin values, and trans-
fusions were recorded.
Results A significant reduction in apparent total blood loss
was detected in the treatment group compared with the control
group. There was also a lower decrease in hemoglobin level,
although this difference was not significant. When fibrin tissue
adhesive was administered, the need for transfusions was
lower. No major adverse events were recorded in our series.
Conclusions Fibrin tissue adhesive reduced blood loss in
TKR and seemed to significantly reduce the need for blood
transfusion. Fibrin tissue adhesive can be an appropriate
solution to enhance hemostasis and vessel sealing at the
operative site in TKR, in order to reduce blood loss after
surgery and the risk of complications.
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Introduction
Total knee replacement (TKR) is associated with major
intra- and postoperative blood loss (approximately
800–1,400 ml), and blood transfusion is frequently
required [1]. Use of tourniquet may reduce intraoperative
blood loss, but postoperative blood loss can still be
considerable.
Decreasing this postoperative blood loss may reduce
patient morbidity [2, 3], length of hospitalization, and costs
by eliminating the need for transfusion.
Various methods of blood preservation have been
studied, in order to avoid transmission of viral diseases and
transfusion reactions; the various perioperative methods
include hemodilution, intraoperative and postoperative
blood salvage and reinfusion [4], hypotensive or epidural
anesthesia, and transfusion of predonated autologous
blood [5].
Obviously, the most appropriate solution is to enhance
hemostasis and vessel sealing at the operative site.
Plasma proteins were used in the past. Modern treatment
with fibrin tissue adhesive, also known as fibrin glue or
fibrin sealant, consists in application of plasma fibrino-
gen mixed with thrombin to form an adhesive fibrin
clot. Since 1972, fibrin sealants have been increasingly
used as hemostatic and sealing agents in a variety of
surgical specialties, including, recently, total knee
replacement [6].
Because of a lack of solid evidence concerning safety
and efficacy, blood-bank products and bovine thrombin
concentrates have been used extensively for many years.
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Fibrin tissue adhesive is composed of two main com-
ponents: fibrinogen and thrombin. When mixed together,
they mimic the last step of the coagulation cascade:
thrombin activates fibrinogen to polymerize to an unstable
clot, and factor XIII, which is present in the fibrinogen
concentrate and is activated by thrombin (factor XIIIa),
stabilizes the clot by catalyzing cross-links between the
fibrin molecules. Factor XIIIa also forms cross-links
between natural plasmin inhibitors (which copurify with
fibrinogen) and the fibrinogen mash to enhance clot resis-
tance against fibrinolysis. Some products contain additional
fibrinolytic inhibitors, such as bovine aprotinin or tranex-
amic acid [7], although the contribution of such additives is
controversial [8].
The desire to avoid any bovine products led to the
development of a second-generation fibrin glue which
replaced bovine aprotinin with tranexamic acid as the
antifibrinolytic agent; safety issues concerning tranexamic
acid led the manufacturer to develop a modified version
without the antifibrinolytic agent [9]. In addition, suc-
cessful application of tissue adhesive needs experience and
training [10].
There are numerous publications concerning good
results of use of fibrin tissue adhesive in all fields of sur-
gery, but many reports are uncontrolled studies and some
trials show no benefits but harmful effects [11]. In ortho-
pedic surgery, the literature is poor and there are few
reports of total knee replacement, for which fibrin glue is
not yet used routinely.
Materials and methods
We designed this study to evaluate the hemostatic efficacy
of fibrin tissue adhesive in patients receiving total knee
arthroplasty. This is a prospective, randomized, standard
treatment controlled study, where the control group had
postoperative blood recovery and reinfusion. Both fibrin
tissue adhesive and postoperative blood reinfusion were
already approved for use in our hospital. We decided to
evaluate the differences between the two procedures, and
the efficacy of fibrin adhesive [5]. The protocol used con-
formed to the Declaration of Helsinki, and we notified the
Ethical Review Board. All patients signed informed written
consent to either procedure before being included in the
study. All patients were enrolled in a program of autolo-
gous blood recovery; for each patient in good health con-
ditions and with good hemoglobin values, we prepared two
units of autologous blood.
We evaluated 70 patients treated for osteoarthritis of the
knee with total knee cementless arthroplasty from April
2009 to April 2010. Exclusion criteria were cemented
TKR, current infection, any kind of cancer, and coagulation
pathology, in order to create two similar groups: treatment
and control.
Thirty-five patients were randomized to receive treat-
ment with fibrin tissue adhesive (the treatment group), and
35 were randomized to be managed with postoperative
blood recovery and reinfusion (control group, Di-deco).
The mean age in the fibrin tissue adhesive group was
70.7 ± 6.4 years, while in the Di-deco group it was
70.4 ± 6.7 years (p = 0.84).
In our series, 54 patients were female and 16 were male
(10 males in the treatment group, 6 in the control group).
The mean presurgery hemoglobin value in the treatment
group was 13.5 ± 1.5 g/dl, and in the control group it was
13.2 ± 1.3 g/dl (p = 0.34).
The mean surgical time was 79 ± 16 min for the
treatment group and 78.2 ± 14.3 min for the control group
(p = 0.84).
The fibrin tissue adhesive used was Quixil (Omrix
Biopharmaceuticals, Belgium), formed by two 5-ml com-
ponents: cryoprecipitated fibrinogen, and a high concen-
tration of human thrombin dissolved in calcium chloride;
an antifibrinolytic agent, tranexamic acid, is added to the
fibrinogen as a stabilizer. Both components undergo double
viral inactivation. The constituents are placed in separate
syringe tubes and mixed by connecting them together to a
single lumen, through which the glue is expelled as a high-
pressure spray.
All total knee arthroplasties were managed by the same
surgical team; a LCS total knee prosthesis cementless
procedure was used for all operations [LCS rotating plat-
form (RP) or LCS anterior–posterior glide (APG) with
posterior cruciate sparing], all performed by medial para-
patellar approach in a bloodless field with use of tourniquet
until prosthesis insertion (Tables 1, 2).
In the treatment group, after the preparation of the femur
and the tibia and before insertion of the prosthesis, the
operative field was rinsed of any debris and meticulously
dried, then the fibrin tissue adhesive (half of 5 ml of each
product component, corresponding to half of the kit) was
applied to the back of the knee cavity, the posterior recess,
the gutters, and the exposed surfaces of the femur and tibia
by topical air pressure spraying with use of a double-syr-
inge spray device from a distance of approximately 15 cm.
Then, after prosthesis insertion, remaining product was
applied over soft tissues, extensor mechanism, and prepa-
tellar bursa, to cover as much surface area as possible with
glue film.
After the tourniquet was deflated (2 min after glue
application), we performed hemostasis of major vessels
using electrocautery. We then placed two drains: one inside
and the other outside of the knee joint.
In the control group, after deflating the tourniquet, we
performed hemostasis of major vessels and connected the
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same two drains to a Di-deco blood recovery device
without fibrin tissue adhesive application.
Hemoglobin and hematocrit values were determined
preoperatively (the day before operation) and on the first
and third postoperative days. Preoperative platelet count,
prothrombin time, and activated partial thromboplastin
time were determined for all patients.
Intraoperative blood loss was similar in the two groups
because of the use of tourniquet and the same operative
technique.
Table 1 Group features
Patient no. Di-deco Quixil
Sex Age (years) Hb before surgery (g/dl) Sex Age (years) Hb before surgery (g/dl)
1 F 67 11.2 F 78 10.5
2 F 69 12 F 78 12.9
3 F 76 13.5 M 69 12.9
4 F 79 11.1 F 78 12.7
5 M 67 12.8 F 63 13.4
6 F 64 13.8 F 53 13.6
7 F 65 12.2 F 73 12.4
8 F 71 11.9 F 75 15.8
9 F 86 15 M 74 15.4
10 F 74 14.7 F 74 15.5
11 F 70 11.7 M 77 13.4
12 F 70 13.9 M 82 14.1
13 F 59 13.1 F 69 12.4
14 F 76 11.7 M 63 15.2
15 F 73 12.3 M 74 15
16 F 79 13.3 F 77 13.3
17 M 68 14.4 m 78 17.5
18 F 71 13.8 F 64 13.1
19 F 73 13.8 F 66 12
20 F 56 11.9 F 75 15.2
21 F 80 13.6 F 78 13.6
22 F 69 11.7 M 77 13.6
23 F 66 11.5 M 60 12.2
24 F 79 14.6 F 67 12.6
25 M 76 13.6 F 71 12
26 M 75 14.4 F 68 11.4
27 M 54 13.2 F 62 14.8
28 F 78 14.2 F 69 13.8
29 F 70 15.8 F 61 14.2
30 F 66 12.4 F 70 13.6
31 F 70 14.4 F 72 10.2
32 F 66 12.9 M 73 14.7
33 M 70 15.6 F 69 13.8
34 F 65 14.6 F 68 14.2
35 F 67 11.7 F 70 12.6
6 males 10 males
Mean 70.4 13.2085714 70.7142857 13.5314286
Median 70 13.3 71 13.6
SD 6.78753182 1.29555154 6.4606111 1.51167446
SD standard deviation
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Table 2 Postoperative findings













1 840 2.5 2aa 90 1,290 0.5 — 90
2 1,100 3.3 1a 70 650 2.8 — 80
3 1,800 3.6 1hb 70 1,420 0.9 — 90
4 1,470 4.4 2h 90 620 2.4 — 70
5 2,650 1.6 2h 115 470 2.8 — 90
6 700 2.7 — 100 400 3.5 — 110
7 1,650 -0.2 — 60 500 1.7 — 70
8 1,480 3.7 2a 60 1,090 5.5 1a 60
9 2,070 2.5 — 70 1,090 2.6 — 70
10 1,120 3.9 — 90 1,050 2.9 — 80
11 1,750 1.6 — 100 650 2.7 — 85
12 1,710 3.8 1h 105 1,150 2.7 1h 90
13 760 5.1 3h 90 910 1.8 — 75
14 800 3 1h 95 1,010 3.8 — 70
15 500 2.9 — 70 650 3.6 — 60
16 700 1.5 — 80 850 2.9 — 60
17 600 3.7 — 80 1,060 2.6 — 65
18 1,200 0.8 — 90 700 2.3 — 100
19 2,350 3.2 1a 60 650 2.8 — 80
20 850 3.4 1h 80 1,000 3.7 — 75
21 800 2.7 — 70 1,070 4.2 — 60
22 1,750 2.9 1h 75 1,150 0.9 — 70
23 2,050 3.1 1h 70 1,480 1.7 1a 100
24 1,750 0.9 — 65 570 1.6 — 110
25 1,850 0 — 70 1,150 0 — 80
26 1,750 3.3 — 90 850 1.6 — 65
27 1,000 0 — 60 1,030 4.8 — 120
28 1,050 3.1 — 70 850 2.3 — 80
29 1,250 4.1 — 65 950 3.6 — 70
30 1,000 2.3 — 80 800 3.2 — 70
31 1,800 2 — 70 370 1.4 1a 70
32 1,100 3.7 2a 70 1,020 2.6 — 65
33 2,050 2.5 — 60 400 2.6 — 65
34 1,050 4 — 70 1,200 2.6 — 65
35 1,800 3.8 1a 90 650 1.6 2h 105
Mean 1,375.71429 2.72571429 78.2857143 878.571429 2.54857143 79
Median 1,250 3 70 910 2.6 75
SD 546.170011 1.28757475 14.3968367 292.485725 1.15970874 16.0788498
a Autologous
b Homologous
Student t test (blood loss): p = 1.6558 9 10-5
Student t test (Hb decrease): p = 0.54736077
Student t test (Hb levels before surgery): p = 0.34083659
Fisher test (blood units administered): 15 patients (Di-deco) versus 6 patients (Quixil): p = 0.03
Fisher test (at least two blood units administered): 12 patients (Di-deco) versus 2 patients (Quixil): p = 0.006
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Blood loss at the end of the operation was recorded by
measuring the volume in the suction apparatus without
washing solution; apparent postoperative blood loss was
recorded by measuring the volume in the suction drain
bottles on the evening of the operation and the first, second,
and third postoperative days (until drain removal).
In the control group, the Di-deco device recovered the
blood loss for the first 6 h after operation; if the blood
amount in this time was sufficient to be washed and pre-
pared (400 ml), it was reinfused. At the end of 6 h, the Di-
deco device was replaced with a suction drain. All Di-deco
reinfusions were recorded.
In all cases (in the treatment group, and in the control
group after Di-deco reinfusion), decisions regarding blood
transfusion were based on hemoglobin value (measured
4–6 h after operation, and on the first, third, and fifth post-
operative days) and clinical conditions, including also car-
diovascular history and patient age, always being used for
hemoglobin values lower than 8 g/dl [12]. The decision to
administer blood was taken by a surgeon blinded to the
patient’s group.
All patients received subcutaneous injection of low-
molecular-weight heparin every evening of the period of
hospitalization, starting the day before surgery.
Any complications, such as wound complications, fever,
prolonged drainage from drain site, and adverse events,
were recorded.
After the first postoperative day, patients began contin-
uous passive motion; all patients were allowed to get out of
bed after the third postoperative day and started physio-
therapy the same day.
The end points of this study are evaluation of the effi-
cacy of fibrin tissue adhesive in reducing blood loss,
decrease of hemoglobin on the first postoperative day, and
the number of transfused units needed by patients. To
evaluate these values we used Student’s t test and Fisher’s
exact test.
Results
The treatment and control groups were comparable in terms
of patient characteristics such as general health conditions,
age, presurgery hemoglobin level (p = 0.34), and surgery
time. As previously stated, intraoperative blood loss was
similar for the two groups because of tourniquet use.
The median apparent postoperative blood loss at drain
removal (third postoperative day) was 910 ± 292 ml in the
fibrin tissue adhesive group compared with 1,250 ± 546 ml
in the control group, and the difference was highly statisti-
cally significant (p = 0.0000165).
The median decrease in hemoglobin concentration on
the first postoperative day was 2.6 ± 1.16 g/dl in the fibrin
tissue adhesive group and 3 ± 1.28 g/dl in the control
group. The difference in this case was not statistically
significant (p = 0.55).
The blood transfusion requirements in the fibrin tissue
adhesive group also were found to be significantly
(p = 0.03) lower than those in the control group; only 5
patients in the fibrin tissue adhesive group required blood
transfusion, and only 1 patient required two units, whereas
15 patients in the control group required blood transfusion,
with 5 requiring two units and 1 requiring three units (for
more than one transfusion unit, p = 0.0057).
Adverse events
Fever was the most common adverse event associated with
surgery, with no difference in frequency between the two
group (six patients in the treatment group, six in the control
group). Hematoma was recorded in two cases in the fibrin
adhesive group and six patients in the control group (one in
the control group needing surgical drainage).
We recorded no superficial wound infection or deep vein
thrombosis. We recorded no embolism in our series after
application of fibrin tissue adhesive by topical spraying
with use of the double-syringe spray device.
Discussion
Many bleeding problems are involved in TKR, not only
intraoperatively but also postoperatively. The amount of
blood loss after total knee arthroplasty is often underesti-
mated because the apparent rate is considered instead of the
calculated blood loss [13].
Intraoperative use of tourniquet (prolonged ischemia in
the limb increases fibrinolytic activity) and suction drain-
age use can increase blood loss.
In many cases it is necessary to transfuse blood units to
avoid a large decrease in hemoglobin values [14, 15]. So, it
appears very useful to adopt the most appropriate solution
to enhance both hemostasis and safety of recovery and
reinfusion [16].
Until last year, in our clinical practice we prepared two
predonated units of autologous blood for all patients in
good health condition (and less than 75 years old), or
prepared two units of homologous blood in the other cases
in addition to use of the Di-deco device. The procedure
regarding preparation of autologous blood units and the
Di-deco device has associated costs, even if they reduce the
necessity for homologous blood transfusions, thus reducing
costs and risk of infection. While autologous predonated
blood is not associated with a risk of viral disease trans-
mission, the rates of administrative error and bacterial
overgrowth after infusion of autologous blood (the two
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factors most frequently associated with immediate post-
transfusion death) are comparable to those associated with
use of homologous blood [17].
Through the use of fibrin sealant we hoped to prevent
the need for recovery and reinfusion due to enhanced
hemostasis in the operative field; use of Quixil was our
choice, so we evaluated in this study the efficacy and safety
of fibrin tissue adhesive in knee replacement as an alter-
native to use of the Di-deco device.
Blood loss in our patients (in both groups) was similar to
mean blood loss reported in literature; a significant
reduction in apparent total blood loss was found in the
group treated with fibrin tissue adhesive compared with the
control group, where the Di-deco device was used. It is
important to underline that, in the control group, not all
patients reached the amount of blood loss needed to trigger
reinfusion until 6 h; in our series, 23 patients (66 %)
received blood recovery from Di-deco.
The treatment group had a smaller postoperative mean
decrease in hemoglobin level than the control group on the
first postoperative day, but this difference was not
significant.
Use of fibrin tissue adhesive significantly reduced the
total number of units of blood transfused postoperatively to
almost one-third of the value in the control group (8 versus
22); it reduced also the rate of patients requiring transfu-
sion to almost one-third (6 versus 15), with only 2 patients
requiring more than one unit, compared with 6 in the
control group.
Since the decision regarding transfusion and the number
of blood units transfused are unreliable values, being
influenced by patient conditions and medical decisions, we
did not consider these parameters as significant.
Prevention of blood loss, including prevention of con-
comitant compartmental shift in body fluid, is definitely
superior to replacement of lost blood. It is much safer for a
patient to receive a multidonor viral-inactivated blood
product (fibrin tissue adhesive) than homologous blood that
cannot be viral inactivated [18].
The results of our study suggest that use of Quixil in
total knee arthroplasty reduces postoperative apparent
blood loss, also compared with use of the Di-deco device.
The Italian Agency of Drugs (AIFA) had informed that
use of a spray device to apply fibrin tissue adhesive can
produce massive embolism (two cases, one fatal, having
been reported). They recommend use of a spray device
with pressure less than 2.0–2.5 bar, to apply Quixil from a
minimal distance of 10–15 cm, and to monitor patients
during spray application. We were informed of these rec-
ommendations after our study, but we did not find any
clinical signs of pulmonary embolism.
The mean cost for a Quixil dose is comparable to the use
of one Di-deco device for each patient; in addition, one
operator is necessary to wash and prepare blood units from
the Di-deco.
We therefore believe that use of fibrin tissue adhesive is
advantageous, as it reduces blood loss; avoiding bleeding
has been shown to be safer than reinfusion, since even
autologous blood is at risk of contamination. Furthermore,
one operator is needed to prepare units, increasing theo-
retical costs.
In conclusion, use of fibrin tissue adhesive was found to
significantly reduce apparent blood loss, also decreasing
costs. On comparison of fibrin glue use with postoperative
blood reinfusion from the Di-deco device in TKR, we
noted a decrease of apparent blood loss, a similar decrease
of hemoglobin values, and transfusions of fewer blood
units, even if it is not possible to define a real decrease of
transfused units due to the variability of patient features.
We believe that fibrin tissue adhesive can be an appro-
priate solution to enhance hemostasis and vessel sealing at
the operative site in order to reduce blood loss and patient
morbidity after surgery.
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